[{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XBiotech\u2019s IND in Rheumatology","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"XB2001","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HZN-457","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PRX-115","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dotinurad","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Urica Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urica Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Urica Therapeutics \/ Fortress Biotech"}]